Ellis Neufeld
Pediatric Hematology-Oncology · Memphis, TNNPI 1215928544
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $222,244 of the $262,897 with a category attached, or 84.5%. 16 manufacturers reported payments, led by Pfizer at 37.5% of the total. Reporting peaked in 2021 at $49,514 and has fallen 59.7% since, to $19,975 in 2025. Among pediatric hematology-oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 131 payments — averaging $2006.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$99K
- Takeda Pharmaceuticals U.S.A., Inc.$41K
- Genentech USA, Inc.$38K
- Merck$34K
- Acceleron Pharma, Inc.$13K
- Novo Nordisk$13K
- plus $26K from 10 others
Across 12 payments — averaging $5644.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$50K
- Octapharma USA, Inc.$7K
- Agios Pharmaceuticals, Inc.$4K
- Acceleron Pharma, Inc.$4K
- HEMA Biologics, LLC$1K
- Bristol Myers Squibb$1K
What the payments were for
- Consulting fees$222,24485%
- Speaking & faculty fees$11,8415%
- Travel & lodging$23,9709%
- Food & beverage$4,8422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 25 | $98,618 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $40,738 |
| Genentech USA, Inc. | 39 | $37,694 |
| Merck | 18 | $33,633 |
| Acceleron Pharma, Inc. | 3 | $12,975 |
| Novo Nordisk | 9 | $12,961 |
| Octapharma USA, Inc. | 3 | $7,084 |
| Bayer | 5 | $4,920 |
| Chiesi USA, Inc. | 4 | $4,795 |
| Agios Pharmaceuticals, Inc. | 2 | $4,070 |
| HEMA Biologics, LLC | 1 | $2,750 |
| Sobi, Inc | 1 | $1,140 |
| Apo-pharma Inc. | 1 | $1,050 |
| Spark Therapeutics, Inc. | 3 | $290 |
| Genentech, Inc. | 2 | $91 |
| Biomarin Pharmaceutical Inc. | 1 | $90 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$262,897 in reported general payments places this provider in the 95th percentile of 113 pediatric hematology-oncology providers in Tennessee.
See all pediatric hematology-oncology providers in Tennessee →
Other pediatric hematology-oncology in Memphis
- Scott HowardMemphis$1.5M
- Deepa ManwaniMemphis$143K
- Akshay SharmaMemphis$92K
- Alberto PappoMemphis$88K
- Ching-Hon PuiMemphis$75K
- Hiroto InabaMemphis$67K
- Caitlyn DuffyMemphis$50K
- Amar GajjarMemphis$45K
- Gary MyersMemphis$44K
- Rohith JesudasMemphis$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.